Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells

Phase 2Active

1 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

B-cell Acute Lymphoblastic Leukemia

Conditions

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory

Trial Timeline

Feb 1, 2022 → Dec 30, 2025

NCT ID

NCT06220097

About Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells

Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells is a phase 2 stage product being developed by CSPC Pharmaceutical Group Limited for B-cell Acute Lymphoblastic Leukemia. The current trial status is active. This product is registered under clinical trial identifier NCT06220097. Target conditions include B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory.

What happened to similar drugs?

3 of 20 similar drugs in B-cell Acute Lymphoblastic Leukemia were approved

Approved (3) Terminated (2) Active (15)

✅IbrutinibJohnson & JohnsonApproved

✅Ibrutinib 420 mg + Ibrutinib 560 mgJohnson & JohnsonApproved

✅Fludarabine Phosphate (Fludara)SanofiApproved

🔄Epcoritamab + Rituximab + Lenalidomide + Oxaliplatin + GemcitabineAbbViePhase 3

🔄Epcoritamab + Investigator's Choice ChemotherapyAbbViePhase 3

🔄acalabrutinib + placebo + Prednisone + Rituximab + Cyclophosphamide + Vincristine + DoxorubicinAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06220097	Phase 2	Active	Feb 1, 2022	Dec 30, 2025	B-cell Acute Lymphoblastic Leukemia

Competing Products

20 competing products in B-cell Acute Lymphoblastic Leukemia

See all competitors

Product	Company	Stage	Hype Score
CD19-CAR-T cells	Avalon GloboCare	Phase 1	19
Sepantronium Bromide	Cothera Bioscience	Phase 2	29
rituximab	Celltrion	Phase 1	21
Valemetostat tosylate	Daiichi Sankyo	Phase 2	39
ASP2802 + MA-20	Astellas Pharma	Phase 1	21
ONTAK (denileukin diftitox)	Eisai	Phase 2	35
Tazemetostat	Eisai	Phase 2	35
Tazemetostat	Eisai	Phase 1	29
ME-401	Kyowa Kirin	Phase 1	29
ME-401	Kyowa Kirin	Phase 2	39
LOXO-338 + Pirtobrutinib	Eli Lilly	Phase 1	33
Pirtobrutinib	Eli Lilly	Pre-clinical	26
Rituximab + Gemcitabine	Eli Lilly	Phase 2	27
Ibrutinib	Johnson & Johnson	Approved	47
Ibrutinib 420 mg + Ibrutinib 560 mg	Johnson & Johnson	Approved	43
ACALABRUTINIB + LISOCABTAGENE MARALEUCEL + Lymphodepleting chemotherapy	Johnson & Johnson	Phase 2	39
VELCADE + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine	Johnson & Johnson	Phase 2	35
Ibrutinib	Johnson & Johnson	Pre-clinical	26
SHR1459 tablet + Efavirenz tablet	Jiangsu Hengrui Medicine	Phase 1	29
SHR1459 ；YY-20394 + SHR1459 ；YY-20394 + Gemcitabine-Oxaliplatin	Jiangsu Hengrui Medicine	Phase 2	31